Our Take
Strong early sales don't fix Novo's structural problem: Lilly owns the market and has better pipeline drugs coming.
Why it matters
Novo needs the pill to work because its next-generation obesity drugs are failing in trials while Lilly advances triple-acting compounds. The prescription gap (18K vs 5.6K weekly) shows early momentum but Lilly's drug launched three months later.
Do this week
Healthcare investors: Compare head-to-head efficacy data before Q3 earnings to assess whether prescription volume translates to sustained market share gains.
Wegovy pill sales hit $354M, nearly double estimates
Novo Nordisk's oral Wegovy generated 2.26 billion Danish kroner ($354 million) in first-quarter sales (company-reported), beating the 1.16 billion kroner consensus estimate by 95% (per Jefferies analyst Michael Leuchten). The company revised its 2026 guidance, now expecting sales and operating profit to decline 4% to 12% versus the prior forecast of 5% to 13%.
The pill launched January 5 and has generated over 2 million prescriptions (company-reported). In its first full week, Wegovy captured 18,000 prescriptions compared to 5,612 for Lilly's competing Foundayo pill in its third week after launching April 9 (per Reuters).
Overall adjusted sales and operating income exceeded Wall Street expectations by 1% and 14% respectively (per Jefferies).
Novo's pipeline problems make pill success critical
The Danish drugmaker has lost ground to Eli Lilly in the GLP-1 market, leading to leadership changes and plans to cut 9,000 jobs. The oral drug represents Novo's best near-term opportunity to regain market share, analysts say.
Novo got a three-month head start over Lilly's Foundayo, which is a new compound rather than an oral version of an existing injectable. In clinical trials, Wegovy pill patients lost more body weight than Foundayo patients, though the drugs haven't been tested head-to-head. Lilly counters that Foundayo doesn't require taking on an empty stomach.
The competitive pressure extends beyond current products. Novo's experimental combination drug CagriSema failed to match Lilly's Zepbound in February trials. Meanwhile, Lilly is advancing a triple-acting drug that showed success in late-stage diabetes and osteoarthritis testing, while Novo's equivalent remains "further behind."
Early wins don't guarantee sustained share
The prescription volume advantage reflects Novo's launch timing and existing relationships rather than proven long-term efficacy. Foundayo's later launch means meaningful market share comparisons won't emerge until Q3 results.
Investors should track whether the 3:1 prescription ratio holds as both drugs build their patient bases. Lilly's convenience advantage and superior pipeline position suggest the early gap may narrow significantly through 2026.